■皮肤利什曼病在伊朗流行。
■我们试图研究皮肤利什曼病患者的治疗结果和治疗并发症。
■本病例系列纳入了2018年至2019年在伊朗访问我们中心的经涂片证实的皮肤利什曼病患者。
■总共,36例患者接受了皮损内的葡甲胺治疗,肌内锑酸葡甲胺,葡萄糖酸钠,和两性霉素B。这种治疗对81.8%的患者有效。6.1%和12.1%的患者出现复发和治疗失败,分别。病灶内治疗,肌内锑酸葡甲胺,葡萄糖酸钠,两性霉素B的清除率为80.8%,92.3%,75%,85.7%,分别。清除与病灶内注射锑酸葡甲胺之间较短的时间间隔相关(p=0.006),复发与注射之间较长的时间间隔相关(p=0.018)。每个患者的平均副作用数量,葡萄糖酸钠,肌内锑酸葡甲胺,两性霉素B分别为0.62,1.4,1.6和2.8.最常见的副作用,肌内锑酸葡甲胺,两性霉素B是局部疼痛,关节痛,和低钾血症,分别。
■低样本量是本研究的局限性。
■肌内注射锑酸葡甲胺的治愈率高于两性霉素B,高于葡萄糖酸钠的治愈率。在病灶内治疗的患者中,缩短注射间隔时间增加了清除率,降低了复发率.
UNASSIGNED: Cutaneous leishmaniasis is endemic in Iran.
UNASSIGNED: We sought to investigate the therapeutic outcomes and complications of treatment in patients with cutaneous leishmaniasis.
UNASSIGNED: This
case series enrolled patients with smear-proven cutaneous leishmaniasis who visited our center in Iran from 2018 to 2019.
UNASSIGNED: In total, 36 patients were treated with intralesional meglumine antimoniate, intramuscular meglumine antimoniate, sodium stibogluconate, and amphotericin B. Overall, this treatment was effective in 81.8 percent of patients. Relapse and treatment failure occurred in 6.1 percent and 12.1 percent of patients, respectively. Treatment with intralesional meglumine antimoniate, intramuscular meglumine antimoniate, sodium stibogluconate, and amphotericin B yielded a clearance rate of 80.8 percent, 92.3 percent, 75 percent, and 85.7 percent, respectively. Clearance was associated with a shorter time interval between injections of intralesional meglumine antimoniate (p=0.006) and relapse was associated with a longer time interval between injections (p=0.018). The average number of side effects per patient for intralesional meglumine antimoniate, sodium stibogluconate, intramuscular meglumine antimoniate, and amphotericin B was 0.62, 1.4, 1.6, and 2.8, respectively. The most common side effect of intralesional meglumine antimoniate, intramuscular meglumine antimoniate, and amphotericin B was local pain, arthralgia, and hypokalemia, respectively.
UNASSIGNED: Low sample size was the limitation of this study.
UNASSIGNED: The cure rate of intramuscular meglumine antimoniate was higher than amphotericin B, which was higher than the cure rate of sodium stibogluconate. In patients treated with intralesional meglumine antimoniate, reducing the time interval between injections increased the clearance rate and decreased the rate of relapse.